Notice: investors in y-mabs therapeutics, inc. with substantial losses have opportunity to lead class action lawsuit – ymab

San diego--( business wire )-- robbins geller rudman & dowd llp announces that purchasers of y-mabs therapeutics, inc. (nasdaq: ymab) common stock on the open market, or pursuant to registration statements filed with the u.s. securities and exchange commission (“sec”), between october 6, 2020 and october 28, 2022, both dates inclusive (the “class period”) have until march 20, 2023 to seek appointment as lead plaintiff. captioned corwin v. y-mabs therapeutics, inc., no. 23-cv-00431 (s.d.n.y.), the y-mabs class action lawsuit charges y-mabs and certain of its top executives with violations of the securities exchange act of 1934.
YMAB Ratings Summary
YMAB Quant Ranking